Salzer W, Asselin B, SUpko, et. al. Erwinina asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013;122(4):507-514
Seiter K. Acute lymphoblastic leukemia treatment & management. [ Medscape Website]. 07/17/2018. Available at: http://emedicine.medscape.com/article/207631-treatment. Accessed October 9, 2019.
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCTAE). V5.0. 11/27/2017. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed October 9, 2019.
US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Approval letter. Asparaginase Erwinia chrysanthemi (Erwinaze®). [FDA Web site]. 03/29/2016. Available at:
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/125359s000ltr.pdf. Accessed October 9, 2019.
C91.00 Acute lymphoblastic leukemia not having achieved remission
C91.02 Acute lymphoblastic leukemia, in relapse
Policy: MA08.007s:Medicare Part B vs. Part D Crossover Drugs
Policy: MA08.012c:Off-label Coverage for Prescription Drugs and/or Biologics